StemCardia — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

StemCardia is a private, pre-clinical stage biotech focused on pioneering heart regeneration therapies using engineered pluripotent stem cell-derived cardiac muscle cells. The company is built upon decades of foundational research from its scientific founders, including landmark studies in primates demonstrating functional benefit. StemCardia is advancing a pipeline of cell and gene therapies through strategic academic and industry partnerships, positioning itself to tackle the massive and growing burden of heart failure.

Cardiovascular DiseaseHeart Failure

Technology Platform

Platform for generating and engineering human pluripotent stem cell-derived cardiomyocytes (PSC-CMs) for transplantation to remuscularize damaged heart tissue. Includes focus on genetic engineering for safety/efficacy and specialized delivery systems.

Opportunities

The massive and growing global heart failure patient population represents a multi-billion dollar market with no curative therapies.

Successfully demonstrating cardiac regeneration in humans would be a paradigm-shifting event, offering first-mover advantage in a transformative new treatment modality.

Strategic partnerships can de-risk development and provide non-dilutive funding.

Risk Factors

High scientific risk in translating primate data to safe and effective human therapies.

Complex, costly manufacturing and scalability challenges for iPSC-derived cell products.

Uncertain regulatory pathway for a first-in-class regenerative therapy.

Future competition from large biopharma and other well-funded biotechs.

Competitive Landscape

The cardiac regeneration space is competitive, with several biotechs (e.g., Capricor Therapeutics, Healios, Cytokinetics in related areas) and large pharma exploring cell-based, gene therapy, and small molecule approaches. StemCardia's key competitive advantages are its deep foundational research from its founders, direct experience in primate models showing functional benefit, and a focused platform on engineered PSC-CMs.

More companies in Cell & Gene Therapy →More companies in United States →